Latest Articles

  • The overlooked and undertreated perils of premature ovarian insufficiency
    Samantha F. Butts, MD, MSCE
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 475-482; DOI: https://doi.org/10.3949/ccjm.92gr.25056

    Physicians should be alert to the possibility of undiagnosed premature ovarian insufficiency—loss of ovarian function before age 40—and know what to do if the condition is suspected.

  • Cerebrovascular complications in infective endocarditis: Challenges and considerations in management
    Cerebrovascular complications in infective endocarditis: Challenges and considerations in management
    Vikyath Satish, MD, Maisha Maliha, MD, Abhyuday Chauhan, MD, Nieves del Mar Morales-Gomez, MD, Safwan Gaznabi, MD, Daniel Lorenzatti, MD, Justin Johannesen, MD, Carlos A. Gongora, MD, Annalisa Filtz, MD, Mario J. Garcia, MD, Leandro Slipczuk, MD, PhD and Aldo L. Schenone, MD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 491-501; DOI: https://doi.org/10.3949/ccjm.92a.24087

    Although the cerebrovascular complications of infective endocarditis such as ischemic strokes and intracranial hemorrhages are common and serious, data remain scarce regarding how best to prevent, predict, and manage them.

  • Evolving paradigms in hypertension management: Fixed-dose single-pill combinations and future therapies
    George Thomas, MD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 471-474; DOI: https://doi.org/10.3949/ccjm.92a.25034

    Despite the availability of effective medications, blood pressure control rates have declined over the past decade, underscoring the need for improved treatment approaches.

  • Does my patient need testing for PFAS ‘forever chemicals’?
    Philip Zuccaro, BS, Damaskini Valvi, MD, MPH, PhD and Vasilis Vasiliou, PhD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 463-465; DOI: https://doi.org/10.3949/ccjm.92a.24082

    Any patient has the right to undergo blood testing for PFAS, but the limitations of testing must be discussed with the patient.

  • Should I consider single-pill combination antihypertensive therapy for my patient with high blood pressure?
    Maximilian C. Volk, DO, Ahmad Safdar, MD and Luke J. Laffin, MD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 467-470; DOI: https://doi.org/10.3949/ccjm.92a.25002

    For many patients, starting treatment with a single-pill combination should be considered for the initial management of hypertension.

  • Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce
    CME article
    Adi E. Mehta, MD, Laura D. Lomeli, BA and Kevin M. Pantalone, DO, ECNU
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 483-489; DOI: https://doi.org/10.3949/ccjm.92a.24113

    Early trials suggested a link between GLP-1 receptor agonists and pancreatitis, but recent large meta-analyses do not support a class-wide risk.

  • Newer diabetes drugs: Surprising shared benefits and unique side effects
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 457-458; DOI: https://doi.org/10.3949/ccjm.92b.08025

    The shared beneficial effects of the SGLT2 inhibitors and the GLP-1 receptor agonists, drugs with distinct mechanisms of action, may have an anti-inflammatory explanation.

  • Managing noninsulin glucose-lowering medications before surgery: A comparison of clinical practice guidelines
    Oscar L. Morey-Vargas, MD, Mona Gossmann, MD, Jeffrey M. Ketz, PharmD and Basem B. Abdelmalak, MD
    Cleveland Clinic Journal of Medicine July 2025, 92 (7) 429-437; DOI: https://doi.org/10.3949/ccjm.92a.24118

    Recommendations for adjusting the treatment regimen of each class of noninsulin glucose-lowering agents before surgery are discussed.

  • Odontogenic cutaneous fistula
    Sagar Khanna, BDS, DDS
    Cleveland Clinic Journal of Medicine July 2025, 92 (7) 399-400; DOI: https://doi.org/10.3949/ccjm.92a.24096

    A 55-year-old woman with a history of systemic lupus erythematosus and secondary Sjögren syndrome presented with a 2-year history of facial swelling and intermittent drainage from a skin lesion on her left jaw.

  • Immunotherapy meets William Shakespeare
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine July 2025, 92 (7) 390-391; DOI: https://doi.org/10.3949/ccjm.92b.07025

    Immune checkpoint inhibitors are potentially life-saving therapies that can trigger a wide range of autoimmune pathology.

Pages